Regulatory News
Tuesday, March 29, 2016
UPDATE 2-FDA panel backs Acadia drug for psychosis linked to Parkinson's
March 29 (Reuters) - An advisory panel to the U.S. Food and
Drug Administration backed an approval for Acadia
Pharmaceuticals Inc's drug for psychosis related to
Parkinson's disease.
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment